Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China

Objective: To evaluate the cost effectiveness of vedolizumab vs. infliximab in the treatment of anti-tumor necrosis factor-alpha (TNF-α)-naïve patients with moderate-to-severe active ulcerative colitis (UC) in China.Methods: The costs and effectiveness of vedolizumab and infliximab in the treatment...

Full description

Bibliographic Details
Main Authors:	Ting Zhou, Yanan Sheng, Haijing Guan, Rui Meng, Zijing Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Public Health
Subjects:	ulcerative colitis vedolizumab infliximab cost-effectiveness analysis China
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2021.704889/full

Similar Items

Treatment of Ulcerative Colitis: Impact on Platelet Aggregation
by: Sasa Peric, et al.
Published: (2023-09-01)

The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
by: Chia-Jung Kuo, et al.
Published: (2022-09-01)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
by: Ayaka Kaneoka, et al.
Published: (2022-02-01)

Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis
by: Raúl Vicente Olmedo-Martín, et al.

Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis Infliximab induce respuesta clínica, endoscópica e histológica en la colitis ulcerosa refractaria
by: F. Bermejo, et al.
Published: (2004-02-01)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01)

Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
by: Keiichi Haga, et al.
Published: (2022-10-01)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
by: Peyman Adibi, et al.
Published: (2011-01-01)

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
by: Gemma Burdge, et al.
Published: (2022-09-01)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
by: Holger Schäffler, et al.
Published: (2017-12-01)

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
by: Taku Kobayashi, et al.
Published: (2021-10-01)

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
by: Kaituo Huang, et al.
Published: (2023-05-01)

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
by: Wilson MR, et al.
Published: (2017-10-01)

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
by: Ido Veisman, et al.
Published: (2021-09-01)

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab
by: A. López San Román, et al.
Published: (2004-06-01)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
by: Friederike Fuchs, et al.
Published: (2017-07-01)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
by: Hiroyuki Okamoto, et al.
Published: (2021-01-01)

A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients
by: Alejandro Pérez-Pitarch, et al.
Published: (2015-03-01)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
by: Yusuke Oki, et al.
Published: (2023-05-01)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
by: Choon Jin Ooi, et al.
Published: (2021-01-01)

Vedolizumab in Inflammatory Bowel Disease: West versus East
by: Prasanta Debnath, et al.
Published: (2021-01-01)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
by: Clotilde Remy, et al.
Published: (2022-12-01)

Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis
by: Wanwan Zhu, et al.
Published: (2022-08-01)

Human herpesvirus 8-associated colonic Kaposi’s sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature
by: Valerio Papa, et al.
Published: (2020-03-01)

Febrile Neutropenia with Thrombocytopenia after Infliximab Induction in a Patient with Ulcerative Colitis
by: Gustavo Gomez, et al.
Published: (2016-10-01)

Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis
by: Mohamed G Fawaz, et al.
Published: (2022-01-01)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
by: Laurent Peyrin‐Biroulet, et al.
Published: (2024-03-01)

Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy
by: Patrizio Armeni, et al.
Published: (2024-03-01)

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?
by: Viscido A, et al.
Published: (2019-04-01)

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
by: Shin Ju Oh, et al.
Published: (2021-07-01)

Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
by: Sujin Choi, et al.
Published: (2021-07-01)

Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review
by: Alix Démaris, et al.
Published: (2022-09-01)

Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab
by: Diana Martins, et al.
Published: (2018-02-01)

Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis
by: Lyu X, et al.
Published: (2023-05-01)

Short-Term Response to Infliximab in Rheumatoid Pattern Polyarthropathy Complicating Ulcerative Colitis
by: ilke Coskun Benlidayi, et al.
Published: (2015-12-01)

Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis
by: Lu Liu, et al.
Published: (2022-06-01)

Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study
by: Aleksandra Sobolewska-Włodarczyk, et al.
Published: (2023-01-01)

Anti-integrin treatment as an effective alternative for a patient with ulcerative colitis
by: Ewa Biegańska, et al.
Published: (2022-12-01)

Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis
by: Jixiang Zhang, et al.
Published: (2022-11-01)

Protracted fever after infliximab induction therapy in a patient with ulcerative colitis (clinical case)
by: E. Yu. Chashkova, et al.
Published: (2022-12-01)